Benayoun L, Letuve S, Druilhe A, Boczkowski J, Dombret M C, Mechighel P, Megret J, Leseche G, Aubier M, Pretolani M
Institut National de la Santé et de la Recherche Médicale (INSERM) Unité 408, Faculté de Médecine Xavier Bichat, Paris, France.
Am J Respir Crit Care Med. 2001 Oct 15;164(8 Pt 1):1487-94. doi: 10.1164/ajrccm.164.8.2101070.
Airway inflammation and alterations in cellular turnover are histopathologic features of asthma. We show that the expression of peroxisome proliferator-activated receptor gamma (PPAR gamma), a nuclear hormone receptor involved in cell activation, differentiation, proliferation, and/or apoptosis, is augmented in the bronchial submucosa, the airway epithelium, and the smooth muscle of steroid-untreated asthmatics, as compared with control subjects. This is associated with enhanced proliferation and apoptosis of airway epithelial and submucosal cells, as assessed by the immunodetection of the nuclear antigen Ki67, and of the cleaved form of caspase-3, respectively, and with signs of airway remodeling, including thickness of the subepithelial membrane (SBM) and collagen deposition. PPAR gamma expression in the epithelium correlates positively with SBM thickening and collagen deposition, whereas PPAR gamma expressing cells in the submucosa relate both to SBM thickening and to the number of proliferating cells. The intensity of PPAR gamma expression in the bronchial submucosa, the airway epithelium, and the smooth muscle is negatively related to FEV(1) values. Inhaled steroids alone, or associated with oral steroids, downregulate PPAR gamma expression in all the compartments, cell proliferation, SBM thickness, and collagen deposition, whereas they increase apoptotic cell numbers in the epithelium and the submucosa. Our findings have demonstrated that PPAR gamma (1) is a new indicator of airway inflammation and remodeling in asthma; (2) may be involved in extracellular matrix remodeling and submucosal cell proliferation; (3) is a target for steroid therapy.
气道炎症和细胞更新改变是哮喘的组织病理学特征。我们发现,过氧化物酶体增殖物激活受体γ(PPARγ)是一种参与细胞激活、分化、增殖和/或凋亡的核激素受体,与对照受试者相比,未经类固醇治疗的哮喘患者支气管黏膜下层、气道上皮和平滑肌中PPARγ的表达增加。这与气道上皮和黏膜下层细胞增殖和凋亡增强有关,分别通过核抗原Ki67和半胱天冬酶-3裂解形式的免疫检测评估,并且与气道重塑迹象有关,包括上皮下膜(SBM)厚度和胶原沉积。上皮中PPARγ表达与SBM增厚和胶原沉积呈正相关,而黏膜下层中表达PPARγ的细胞与SBM增厚和增殖细胞数量均有关。支气管黏膜下层、气道上皮和平滑肌中PPARγ表达强度与第一秒用力呼气容积(FEV1)值呈负相关。单独吸入类固醇或与口服类固醇联合使用,可下调所有区域的PPARγ表达、细胞增殖、SBM厚度和胶原沉积,而它们会增加上皮和黏膜下层的凋亡细胞数量。我们的研究结果表明,PPARγ(1)是哮喘气道炎症和重塑的新指标;(2)可能参与细胞外基质重塑和黏膜下层细胞增殖;(3)是类固醇治疗的靶点。